Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE May 26, 2017

Immune Receives Nasdaq Letters | Read more 


May 4, 2017

Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million | Read more 


PRESS RELEASE April 24, 2017

Immune Pharmaceuticals Announces Corporate Restructuring | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events